Stoke Therapeutics, Inc

(NASDAQ:STOK)

Latest On Stoke Therapeutics, Inc (STOK):

Date/Time Type Description Signal Details
2023-05-04 17:05 ESTNewsStoke Therapeutics GAAP EPS of -$0.53 beats by $0.15, revenue of $5.15M beats by $1.65MN/A
2023-05-01 14:11 ESTNewsStoke Therapeutics upgraded to neutral at BoA on Dravet candidateN/A
2023-04-26 22:19 ESTNewsStoke Therapeutics a buy at Canaccord on platform for genetic diseasesN/A
2023-04-25 22:00 ESTNewsStoke stock rises after UK regulator nod to start trial of eye disorder drugN/A
2023-03-15 17:15 ESTNewsStoke gets FDA nod to use higher dose of epilepsy drug in ongoing trialN/A
2023-03-06 19:36 ESTNewsStoke Therapeutics GAAP EPS of -$0.65 beats by $0.05, revenue of $3.27M beats by $0.41MN/A
2023-02-12 09:04 ESTNewsStoke Therapeutics Looks Unfairly ValuedN/A
2022-11-28 18:27 ESTNewsBuy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeN/A
2022-11-14 15:38 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $2.91M beats by $0.19MN/A
2022-11-14 15:37 ESTNewsStoke Therapeutics drops 27% after early data for anti-seizure medicineN/A
2022-08-09 08:23 ESTNewsStoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18MN/A
2022-05-10 14:29 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.98, revenue of $3M misses by $34.5MN/A
2022-03-10 22:22 ESTNewsStoke Therapeutics GAAP EPS of -$0.66 misses by $0.04N/A
2022-01-31 23:13 ESTNewsStoke Therapeutics initiated Buy at Jefferies on potential of RNA platformN/A
2022-01-25 02:45 ESTNewsStoke Therapeutics (STOK) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2021-12-03 21:14 ESTNewsStoke Therapeutics shares data from Phase 1/2a trial for STK-001 in Dravet syndromeN/A
2021-12-01 09:31 ESTNewsWarning: STOK is at high risk of performing badlyN/A
2021-12-01 09:31 ESTNewsStoke Therapeutics (STOK) Investor Presentation -SlideshowN/A
2021-11-23 08:45 ESTNewsStoke Therapeutics up 14% following J.P. Morgan upgrade to overweightN/A
2021-11-08 19:21 ESTNewsStoke Therapeutics EPS misses by $0.02N/A
2021-09-22 07:07 ESTNewsStoke Therapeutics posts interim results from early-stage STK-001 Dravet syndrome studyN/A
2021-08-10 12:23 ESTNewsStoke Therapeutics EPS misses by $0.12N/A
2021-03-30 13:19 ESTNewsStoke Therapeutics gets MHRA greenlight for early-stage Dravet syndrome studyN/A
2021-03-11 20:54 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 12:29 ESTAnalyst RatingThe Analyst Target Price has increased from $63.75 to $65.38.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-11 00:51 ESTAnalyst RatingThe Analyst Target Price has increased from $60.38 to $63.75.Buy
2021-03-11 00:51 ESTEarnings EstimateAn EPS average of -$2.12 is estimated for the 2022 year.Sell
2021-03-10 04:53 ESTFinancialsCompany financials have been released.Neutral
2021-03-07 14:56 ESTNewsSizing Up Stoke TherapeuticsN/A
2021-02-11 08:36 ESTAnalyst RatingThe Analyst Target Price has increased from $59.5 to $60.38.Neutral
2021-02-10 19:01 ESTNewsStoke cut to neutral at Wedbush seeking a ‘better entry point’N/A
2021-01-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $57.63 to $59.5.Neutral
2021-01-15 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $56.5 to $57.63.Neutral
2020-12-29 08:37 ESTAnalyst RatingThe Analyst Target Price has increased from $54.13 to $56.5.Neutral
2020-12-16 13:07 ESTAnalyst RatingThe Analyst Target Price has increased from $49.13 to $54.13.Neutral
2020-12-14 08:52 ESTAnalyst RatingThe Analyst Target Price has increased from $48.13 to $49.13.Neutral
2020-12-14 08:12 ESTNewsStoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market CapN/A
2020-11-26 21:40 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 03:45 ESTNewsStoke Therapeutics prices $97.5M public offeringN/A
2020-11-19 00:23 ESTNewsStoke Therapeutics -2.7% AH, proposes public offeringN/A
2020-11-17 05:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:28 ESTAnalyst RatingThe Analyst Target Price has increased from $47.13 to $48.13.Buy
2020-11-14 21:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:26 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-13 13:26 ESTAnalyst RatingThe Analyst Target Price has increased from $41.5 to $47.13.Buy
2020-11-13 10:25 ESTNewsStoke Therapeutics EPS in-lineN/A
2020-11-08 00:59 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 18:01 ESTInsider TradeHuw M. Nash has directly disposed of 2,536 shares and currently holds 0 shares.Sell

About Stoke Therapeutics, Inc (STOK):

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Quotes by TradingView

See Advanced Chart

General

  • Name Stoke Therapeutics, Inc
  • Symbol STOK
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 79
  • Fiscal Year EndDecember
  • IPO Date2019-06-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.stoketherapeutics.com
View More

Valuation

  • Trailing PE 21.65
  • Price/Book (Most Recent Quarter) 6.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.80
  • Next Year EPS Estimate -$2.10
  • Next Quarter EPS Estimate -$0.44
  • Return on Assets -13%
  • Return on Equity -20%
  • Earnings Per Share -$11.44
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.78 billion
  • EBITDA -22302000
  • PE Ratio -7.4
  • Analyst Target Price $65.38
  • Book Value Per Share $7.14
View More

Share Statistics

  • Shares Outstanding 36.66 million
  • Shares Float 12.64 million
  • % Held by Insiders 170%
  • % Held by Institutions 98.06%
  • Shares Short 3.3 million
  • Shares Short Prior Month 3.37 million
  • Short Ratio 27.54
  • Short % of Float 21%
  • Short % of Shares Outstanding 9%
View More

Technicals

  • 52 Week High $71.58
  • 52 Week Low $17.55
  • 50 Day Moving Average 58.62
  • 200 Day Moving Average 48.97
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Stoke Therapeutics, Inc (STOK) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Stoke Therapeutics, Inc (STOK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.42-$0.420.92%
2020-09-302020-11-12$N/A-$0.41-$0.434.58%
2020-06-302020-08-10$N/A-$0.39-$0.36-8.33%
2020-03-312020-05-15$N/A-$0.34-$0.378.87%
2019-12-312020-03-23$N/A-$0.09-$0.3069.63%
2019-09-302019-11-12$N/A-$0.26-$0.285.83%
2019-06-302019-08-14$N/A-$1.54-$1.635.39%

Stoke Therapeutics, Inc (STOK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 8.9 million N/A N/A 7.22 million 7.09 million
Income Before Tax -14.56 million N/A N/A -11.04 million -10.16 million
Selling General Administrative 5.68 million N/A N/A 4.52 million 3.98 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -14.35 million N/A N/A -11.54 million -11.07 million
Operating Income -14.59 million N/A N/A -11.74 million -11.07 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 15000 N/A N/A 22000 908000
Net Income From Continuing Operations -14.56 million N/A N/A -11.04 million -10.16 million
Net Income Applicable to Common Shares -14.56 million -13.68 million -12.96 million N/A -10.16 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -269000 -81000 -610000 N/A N/A
Change to Liabilities 610000 N/A N/A N/A N/A
Total Cash Flow from Investing Activities -269000 N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 673000 369000 198000 N/A N/A
Change to Operating Activities -80000 N/A N/A N/A N/A
Change in Cash -10.47 million -9.36 million -11.18 million N/A N/A
Total Cash from Operating Activities -10.87 million -9.65 million -10.77 million N/A N/A
Depreciation 234000 224000 193000 N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -360000 N/A N/A N/A N/A
Change to Net Income 2.05 million N/A N/A N/A N/A
Capital Expenditures 269000 81000 610000 N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 11.85 million N/A N/A 6.5 million 4.32 million
Total Stockholder Equity 286.08 million N/A N/A 214.34 million 224.43 million
Other Current Liabilities N/A N/A N/A 54000 N/A
Total Assets 297.93 million N/A N/A 220.84 million 228.75 million
Common Stock 4000 3000 3000 N/A 3000
Other Current Assets 6.62 million 378000 N/A N/A N/A
Retained Earnings -110.28 million -95.72 million -82.03 million -69.07 million -58.04 million
Other Liabilities N/A 665000 1.01 million N/A 221000
Other Assets N/A 205000 205000 N/A 205000
Cash 287.31 million N/A N/A 211.29 million 222.47 million
Total Current Liabilities 11.43 million 6.74 million N/A 5.46 million 4.1 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 2.68 million 4.27 million 4.47 million N/A 2.51 million
Total Current Assets 293.93 million 195.46 million N/A 215.77 million 226.03 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 286.08 million 192.54 million 203.4 million N/A 224.43 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 11.43 million 1.1 million N/A 1.78 million 751000

Stoke Therapeutics, Inc (STOK) Chart:

Stoke Therapeutics, Inc (STOK) News:

Below you will find a list of latest news for Stoke Therapeutics, Inc (STOK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Stoke Therapeutics, Inc (STOK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-05-1512.50CALL0 110TRUE00
2026-05-151517.89CALL0 0538.86TRUE00
2026-05-1517.50CALL0 194479.59TRUE00
2026-05-152013.7CALL0 230TRUE00
2026-05-1522.59CALL0 49313.79TRUE00
2026-05-15250CALL0 80TRUE00
2026-05-15303.1CALL0 21119.4TRUE00
2026-05-15350.66CALL0 97292.82FALSE00
2026-05-15400.3CALL0 119273.43FALSE00
2026-05-15450CALL0 297283.03FALSE00
2026-05-15500CALL0 164583.78FALSE00
2026-05-15550CALL0 0648.12FALSE00
2026-05-1512.50PUT0 20758.92FALSE00
2026-05-15150PUT0 151076.74FALSE00
2026-05-1517.50PUT0 16909.1FALSE00
2026-05-15200.05PUT40 77265.87FALSE0.050
2026-05-1522.50PUT0 14361.11FALSE00
2026-05-15250.17PUT0 21220.08FALSE00
2026-05-15300.71PUT0 2289119.26FALSE00
2026-05-15352.96PUT0 126110.34TRUE00
2026-05-15400PUT0 1173.95TRUE00
2026-05-15450PUT0 1241.06TRUE00
2026-05-155016.87PUT0 0297.03TRUE00
2026-05-15550PUT0 0401.14TRUE00
2026-06-1817.50CALL0 0126TRUE00
2026-06-182013.1CALL0 31118.51TRUE00
2026-06-1822.50CALL0 0111.62TRUE00
2026-06-18250CALL0 085.33TRUE00
2026-06-18305.03CALL1 490.74TRUE-0.47-0.09
2026-06-18352.68CALL1 4088FALSE2.680
2026-06-18401.3CALL0 761.92FALSE00
2026-06-18450CALL0 0143.91FALSE00
2026-06-18500CALL0 2165.55FALSE00
2026-06-18550CALL0 1183.91FALSE00
2026-06-1817.50PUT0 0259.81FALSE00
2026-06-18200PUT0 098.2FALSE00
2026-06-1822.50PUT0 0183.3FALSE00
2026-06-18250PUT0 092.13FALSE00
2026-06-18302.2PUT1 084.49FALSE2.20
2026-06-18354.07PUT0 866.5TRUE00
2026-06-18408.27PUT0 892.27TRUE00
2026-06-18450PUT0 085.92TRUE00
2026-06-185017.6PUT0 1987.45TRUE00
2026-06-18550PUT0 086.59TRUE00
2026-08-2117.50CALL0 295.25TRUE00
2026-08-21200CALL0 790.27TRUE00
2026-08-2122.50CALL0 389.23TRUE00
2026-08-21250CALL0 2286.59TRUE00
2026-08-21307CALL0 3880.08TRUE00
2026-08-21354.58CALL0 8178.45FALSE00
2026-08-21402.9CALL0 3781.61FALSE00
2026-08-21453.2CALL1 1098.22FALSE1.150.56
2026-08-21500CALL0 30100.27FALSE00
2026-08-21551.05CALL0 12110.58FALSE00
2026-08-2117.50PUT0 20158.33FALSE00
2026-08-21200PUT0 1383.86FALSE00
2026-08-2122.50PUT0 6113.15FALSE00
2026-08-21250PUT0 693.39FALSE00
2026-08-21300PUT0 2982.48FALSE00
2026-08-21356.6PUT0 5875.99TRUE00
2026-08-21400PUT0 179.06TRUE00
2026-08-21450PUT0 2880.4TRUE00
2026-08-21500PUT0 3483.37TRUE00
2026-08-21550PUT0 084.31TRUE00
2026-11-2017.50CALL0 393.09TRUE00
2026-11-20200CALL0 192.13TRUE00
2026-11-2022.50CALL0 088.79TRUE00
2026-11-20250CALL0 084.04TRUE00
2026-11-20300CALL0 1482.35TRUE00
2026-11-20350CALL0 079FALSE00
2026-11-20406CALL0 180.2FALSE00
2026-11-20450CALL0 278.4FALSE00
2026-11-20503.48CALL0 580.81FALSE00
2026-11-2017.51.35PUT0 1117.01FALSE00
2026-11-20200PUT0 399FALSE00
2026-11-2022.50PUT0 490.92FALSE00
2026-11-20250PUT0 084.37FALSE00
2026-11-20300PUT0 083.23FALSE00
2026-11-20358.75PUT0 280.52TRUE00
2026-11-20400PUT0 081.75TRUE00
2026-11-20450PUT0 081.86TRUE00
2026-11-20500PUT0 081.08TRUE00

Latest STOK Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST13$10.47
Jun 13, 2022 7:59 PM EST60$10.47
Jun 13, 2022 7:59 PM EST20$10.47
Jun 13, 2022 7:59 PM EST41$10.47
Jun 13, 2022 7:59 PM EST15$10.47

Stoke Therapeutics, Inc (STOK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2019-04-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019007260/0000000000-19-007260-index.htm
2019-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019008485/0000000000-19-008485-index.htm
2019-06-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009270/0000000000-19-009270-index.htm
2019-06-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000019009719/0000000000-19-009719-index.htm
2020-07-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1623526/000000000020006449/0000000000-20-006449-index.htm
2019-07-01SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963819000658/0000929638-19-000658-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000092963820000333/0000929638-20-000333-index.htm
2019-03-26DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319002845/0000950123-19-002845-index.htm
2019-04-30DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003688/0000950123-19-003688-index.htm
2019-04-30DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1623526/000095012319003690/0000950123-19-003690-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000110465920021017/0001104659-20-021017-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419031374/0001144204-19-031374-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000114420419032095/0001144204-19-032095-index.htm
2019-05-23S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519155301/0001193125-19-155301-index.htm
2019-05-23CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519155321/0001193125-19-155321-index.htm
2019-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519163789/0001193125-19-163789-index.htm
2019-06-07S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519167576/0001193125-19-167576-index.htm
2019-06-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519167579/0001193125-19-167579-index.htm
2019-06-118-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519170268/0001193125-19-170268-index.htm
2019-06-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312519171310/0001193125-19-171310-index.htm
2019-06-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519171314/0001193125-19-171314-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173255/0001193125-19-173255-index.htm
2019-06-14CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312519173266/0001193125-19-173266-index.htm
2019-06-19S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312519175848/0001193125-19-175848-index.htm
2019-06-18S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519175863/0001193125-19-175863-index.htm
2019-06-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1623526/000119312519176488/0001193125-19-176488-index.htm
2019-07-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1623526/000119312519186323/0001193125-19-186323-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519220567/0001193125-19-220567-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312519308649/0001193125-19-308649-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520005877/0001193125-20-005877-index.htm
2020-03-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520082470/0001193125-20-082470-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520108110/0001193125-20-108110-index.htm
2020-04-21DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113542/0001193125-20-113542-index.htm
2020-04-21DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1623526/000119312520113561/0001193125-20-113561-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520139879/0001193125-20-139879-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520160684/0001193125-20-160684-index.htm
2020-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520189990/0001193125-20-189990-index.htm
2020-07-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1623526/000119312520191098/0001193125-20-191098-index.htm
2020-07-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1623526/000119312520193961/0001193125-20-193961-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520221818/0001193125-20-221818-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520226962/0001193125-20-226962-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000119312520265127/0001193125-20-265127-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021312/0001209191-20-021312-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021314/0001209191-20-021314-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021317/0001209191-20-021317-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021319/0001209191-20-021319-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021321/0001209191-20-021321-index.htm
2020-03-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120021322/0001209191-20-021322-index.htm
2020-04-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024540/0001209191-20-024540-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-04-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032142/0001209191-20-032142-index.htm
2020-05-264/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032146/0001209191-20-032146-index.htm
2020-05-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034721/0001209191-20-034721-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034723/0001209191-20-034723-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034729/0001209191-20-034729-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034731/0001209191-20-034731-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034732/0001209191-20-034732-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034735/0001209191-20-034735-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120034737/0001209191-20-034737-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-07-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-10-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-06-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1623526/000135445719000309/0001354457-19-000309-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009407/0001493152-19-009407-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219009851/0001493152-19-009851-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1623526/000149315220002386/0001493152-20-002386-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019032126/0001564590-19-032126-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459019042621/0001564590-19-042621-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459019042891/0001564590-19-042891-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020012112/0001564590-20-012112-index.htm
2020-03-2310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1623526/000156459020012202/0001564590-20-012202-index.htm
2020-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020025636/0001564590-20-025636-index.htm
2020-05-1510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020025637/0001564590-20-025637-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1623526/000156459020038587/0001564590-20-038587-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1623526/000156459020038905/0001564590-20-038905-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013623/0001567619-19-013623-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013624/0001567619-19-013624-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013625/0001567619-19-013625-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013626/0001567619-19-013626-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013627/0001567619-19-013627-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013628/0001567619-19-013628-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013629/0001567619-19-013629-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013630/0001567619-19-013630-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013631/0001567619-19-013631-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013632/0001567619-19-013632-index.htm
2019-06-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013633/0001567619-19-013633-index.htm
2019-06-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013662/0001567619-19-013662-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018220/0001567619-19-018220-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018221/0001567619-19-018221-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018222/0001567619-19-018222-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018223/0001567619-19-018223-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018224/0001567619-19-018224-index.htm
2019-09-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919018225/0001567619-19-018225-index.htm
2019-11-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021770/0001567619-19-021770-index.htm
2019-11-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000156761919021771/0001567619-19-021771-index.htm
2014-11-24DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352614000001/0001623526-14-000001-index.htm
2018-11-02DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1623526/000162352618000002/0001623526-18-000002-index.htm
2019-06-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999519001367/9999999995-19-001367-index.htm
2020-07-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1623526/999999999520001866/9999999995-20-001866-index.htm
2019-06-03SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005333/9999999997-19-005333-index.htm
2019-06-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1623526/999999999719005455/9999999997-19-005455-index.htm

Stoke Therapeutics, Inc (STOK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Stoke Therapeutics, Inc (STOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 170%
Institutional Ownership: 9806%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-03-02Huw M. NashCOO & CBOSell15,995.0026.37421,852.130.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell500.0027.4813,742.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-07-01Huw M. NashCOO & CBOSell3,800.0023.1587,967.720.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-07-07Huw M. NashCOO & CBOSell913.0022.4120,456.860.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042004/0001209191-20-042004-index.htm
2020-07-16Huw M. NashCOO & CBOSell1,900.0025.0647,614.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-08-03Huw M. NashCOO & CBOSell5,700.0024.73140,943.330.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-08-28Huw M. NashCOO & CBOSell2,081.0030.0062,430.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-09-01Huw M. NashCOO & CBOSell700.0028.7120,097.630.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-09-08Huw M. NashCOO & CBOSell30,718.0030.00921,540.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-09-09Huw M. NashCOO & CBOSell17,201.0030.00516,030.000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-10-01Huw M. NashCOO & CBOSell2,300.0034.8680,182.600.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOSell2,536.0037.9896,324.890.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-07-07Robin A. WalkerChief Legal Officer, CCO & SecSell941.0022.5021,172.500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042007/0001209191-20-042007-index.htm
2020-11-02Stephen J TulipanoCFOSell14,445.0037.86546,909.371,002.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy131,147.000.6078,688.20131,147.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-03-31Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevSell7,500.0030.00225,000.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell1,230.0027.4833,801.5113,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevSell1,649.0040.0065,960.0013,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevSell5,851.0040.00234,041.7613,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell7,225.0038.42277,585.9513,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell7,875.0026.91211,920.9814,730.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-13Gene LiauEVP Research & Preclinical DevBuy1,649.000.60989.4015,149.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120054703/0001209191-20-054703-index.htm
2020-11-02Stephen J TulipanoCFOSell20,155.0036.79741,448.0315,447.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOSell33,148.0025.66850,697.0115,995.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2019-06-21Apple Tree Partners IV, L.P.10% Share HolderBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013838/0001567619-19-013838-index.htm
2019-06-21Seth Loring HarrisonDirectorBuy1,388,889.0018.0025,000,002.0016,786,713.00https://www.sec.gov/Archives/edgar/data/1623526/000156761919013840/0001567619-19-013840-index.htm
2020-11-04Stephen J TulipanoCFOSell16,941.0040.03678,085.5516,929.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-09-09Huw M. NashCOO & CBOBuy17,201.002.1937,670.1917,201.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Barry TichoChief Medical OfficerSell365.0027.9810,212.70172,662.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerSell1,000.0027.1727,174.00173,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-06-01Barry TichoChief Medical OfficerBuy42,880.002.1993,907.20174,027.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034101/0001209191-20-034101-index.htm
2020-07-16Huw M. NashCOO & CBOBuy1,900.002.194,161.001,900.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120042943/0001209191-20-042943-index.htm
2020-10-16Gene LiauEVP Research & Preclinical DevBuy5,851.000.603,510.6019,351.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevSell24,775.0037.64932,578.0720,725.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-08-28Huw M. NashCOO & CBOBuy2,081.002.194,557.392,081.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120048841/0001209191-20-048841-index.htm
2020-05-22Gene LiauEVP Research & Preclinical DevBuy7,500.000.604,500.0021,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120032149/0001209191-20-032149-index.htm
2020-06-01Huw M. NashCOO & CBOBuy2,107.002.194,614.332,107.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevSell10,895.0025.82281,314.3522,605.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2020-10-01Huw M. NashCOO & CBOSell3,400.0034.33116,717.922,300.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-03Stephen J TulipanoCFOBuy1,732.004.487,759.362,334.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-02Huw M. NashCOO & CBOSell3,164.0036.59115,785.002,536.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-09-08Huw M. NashCOO & CBOBuy30,718.002.1967,272.4230,718.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120050031/0001209191-20-050031-index.htm
2020-06-01Gene LiauEVP Research & Preclinical DevBuy20,000.002.1943,800.0033,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034096/0001209191-20-034096-index.htm
2019-06-19RTW INVESTMENTS, LP10% Share HolderBuy555,556.0018.0010,000,008.003,355,466.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219009471/0001493152-19-009471-index.htm
2020-11-04Stephen J TulipanoCFOBuy33,268.004.48149,040.6433,870.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-10-01RTW INVESTMENTS, LP10% Share HolderBuy31,560.0021.96693,029.203,387,026.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219014877/0001493152-19-014877-index.htm
2019-10-30RTW INVESTMENTS, LP10% Share HolderBuy41,438.0028.791,193,004.163,428,464.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-10-31RTW INVESTMENTS, LP10% Share HolderBuy18,747.0028.15527,658.693,447,211.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-01RTW INVESTMENTS, LP10% Share HolderBuy8,598.0028.61245,950.093,455,809.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016346/0001493152-19-016346-index.htm
2019-11-08RTW INVESTMENTS, LP10% Share HolderSell16,434.0028.70471,631.153,544,248.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016926/0001493152-19-016926-index.htm
2020-11-02Stephen J TulipanoCFOBuy35,000.004.48156,800.0035,602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-11-04RTW INVESTMENTS, LP10% Share HolderBuy104,873.0029.243,066,843.093,560,682.00https://www.sec.gov/Archives/edgar/data/1623526/000149315219016566/0001493152-19-016566-index.htm
2020-07-01Huw M. NashCOO & CBOBuy3,800.002.198,322.003,800.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120040613/0001209191-20-040613-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy30,497.000.6018,298.2043,997.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-10-19Gene LiauEVP Research & Preclinical DevBuy1,503.002.193,291.5745,500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120055378/0001209191-20-055378-index.htm
2020-03-02Huw M. NashCOO & CBOBuy42,779.002.1993,686.0149,103.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-06-01Huw M. NashCOO & CBOSell1,607.0027.0843,521.26500.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120034091/0001209191-20-034091-index.htm
2019-12-16Edward M. MD KayeCEOBuy50,000.000.6030,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024543/0001209191-20-024543-index.htm
2020-08-03Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120044723/0001209191-20-044723-index.htm
2020-09-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm
2020-10-01Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120053732/0001209191-20-053732-index.htm
2020-11-02Huw M. NashCOO & CBOBuy5,700.002.1912,483.005,700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056950/0001209191-20-056950-index.htm
2020-11-04Stephen J TulipanoCFOSell11,111.0041.42460,214.295,818.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2019-12-20Gene LiauEVP Research & Preclinical DevBuy6,000.000.603,600.006,000.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120024546/0001209191-20-024546-index.htm
2020-11-02Stephen J TulipanoCFOSell400.0038.4415,374.00602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-03Stephen J TulipanoCFOSell1,732.0039.8468,997.51602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-11-04Stephen J TulipanoCFOSell5,216.0041.97218,909.78602.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120056953/0001209191-20-056953-index.htm
2020-03-02Huw M. NashCOO & CBOBuy6,324.000.402,529.606,324.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120016360/0001209191-20-016360-index.htm
2020-09-01Huw M. NashCOO & CBOSell5,000.0027.60138,015.00700.00https://www.sec.gov/Archives/edgar/data/1623526/000120919120049551/0001209191-20-049551-index.htm